» Articles » PMID: 34886817

IL-6 and IL-10 Gene Polymorphisms and Cirrhosis of Liver Risk from a Comprehensive Analysis

Overview
Publisher Biomed Central
Specialty Endocrinology
Date 2021 Dec 10
PMID 34886817
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Different inflammatory and immune cytokines play a key role in the development of cirrhosis of liver (CL). To investigate the association between interleukin-6,10 (IL-6,10) genes polymorphisms and CL risk through comparison of the allele and genotype distribution frequencies by meta-analysis.

Methods: A literature search covered with the PubMed, Embase, Cochrane Library, Web of Science, Google Scholar, SinoMed (CNKI and Wanfang) through 20th April, 2021. Odds ratios (OR) and 95% confidence intervals (CI) were used to assess the strength of associations.

Results: After a comprehensive search, three common polymorphisms (rs1800872, rs1800871, rs1800896) in IL-10 gene were selected, and three common polymorphisms (rs1800795, rs1800796, rs1800797) in IL-6 gene were also identified. The important finding was that IL-10 rs1800872 was a risk factor for CL development. For example, there has a significantly increased relationship between rs1800872 polymorphism and CL both in the whole group (OR: 1.30, 95%CI: 1.01-1.67 in heterozygote model), Asian population (OR: 1.40, 95%CI: 1.03-1.88 in heterozygote model) and hospital-based source of control (OR: 1.40, 95%CI: 1.01-1.96 in dominant model). In addition, significant association was found between rs1800896 and primary biliary cirrhosis subtype disease (OR: 1.30, 95%CI: 1.01-1.68 in allelic contrast model). No association was observed in all three polymorphisms in IL-6 gene.

Conclusion: Our present study suggests that the IL-10 rs1800872 and rs1800896 polymorphisms is potentially associated with the risk of CL susceptibility.

Citing Articles

From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.

Porada M, Buldak L Metabolites. 2025; 15(2).

PMID: 39997697 PMC: 11857179. DOI: 10.3390/metabo15020072.


Copaiba Oleoresin Improves Weight Gain and IL-10 Concentration, with No Impact on Hepatic Histology, in Liver Cirrhosis.

Taffarel M, Silva B, Paulino A, Telles L, Mendonca S, Santos C Biology (Basel). 2024; 13(11).

PMID: 39596809 PMC: 11591688. DOI: 10.3390/biology13110853.


Associations between single nucleotide polymorphisms of cytokines and hepatitis B virus-related liver cirrhosis: A case-control study.

Li Y, Zhou H, Wu W, Zhang W, Ye Y, Jia W Immun Inflamm Dis. 2024; 12(9):e70017.

PMID: 39315805 PMC: 11421045. DOI: 10.1002/iid3.70017.


The rs361525 and rs2430561 polymorphisms are associated with liver cirrhosis risk: a comprehensive meta-analysis.

Zheng M, Li J, Fang W, Luo L, Ding R, Zeng H Front Immunol. 2023; 14:1129767.

PMID: 37122734 PMC: 10140545. DOI: 10.3389/fimmu.2023.1129767.


Gene polymorphisms of inflammatory factors in liver cirrhosis.

Xiao S, Pan X, Huang X, Liu Y, Wen S, Liu A Front Genet. 2023; 14:1140427.

PMID: 37101651 PMC: 10123281. DOI: 10.3389/fgene.2023.1140427.

References
1.
Motawi T, Shaker O, Hussein R, Houssen M . Polymorphisms of α1-antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection. Balkan J Med Genet. 2017; 19(2):35-44. PMC: 5343329. DOI: 10.1515/bjmg-2016-0034. View

2.
Chen Q, Fan L, Zhong R, Tu X, Yuan Y, Zhu Y . [A study on the relationship between interleukin-10 promoter polymorphism and autoimmune liver disease]. Zhonghua Gan Zang Bing Za Zhi. 2004; 12(6):356-8. View

3.
Zhang S, Yang X, Wang W . Associations of genetic polymorphisms in CTLA-4 and IL-18 with chronic liver diseases: Evidence from a meta-analysis. Genomics. 2019; 112(2):1889-1896. DOI: 10.1016/j.ygeno.2019.11.001. View

4.
Hsiang J, Bai W, Raos Z, Stableforth W, Upton A, Selvaratnam S . Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. Intern Med J. 2014; 45(2):160-9. DOI: 10.1111/imj.12624. View

5.
. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5(3):245-266. PMC: 7026710. DOI: 10.1016/S2468-1253(19)30349-8. View